期刊文献+

复方二氯二异丙胺治疗酒精性脂肪性肝病疗效观察

The efficacy of compound dichloride diisopropylamine in the treatment of alcoholic fatty liver disease
下载PDF
导出
摘要 目的:探讨复方二氯二异丙胺治疗酒精性脂肪性肝病患者的临床疗效及安全性。方法将97例酒精性脂肪性肝病患者随机分为两组,研究组54例,对照组43例。研究组静脉滴注复方二氯二异丙胺治疗,对照组常规口服胰岛素增敏剂二甲双胍治疗,观察6周。于治疗6周末,根据血清总胆固醇改善状况判定临床疗效,并统计不良反应发生状况。结果治疗6周末,研究组总有效率为98.1%,对照组为81.4%;两组比较差异有极显著性(P<0.01)。研究组不良反应发生率为7.4%,对照组为14.0%;两组比较差异无显著性(P>0.05)。结论复方二氯二异丙胺治疗酒精性脂肪性肝病患者疗效显著,安全性高,值得在临床广泛推广应用。 Objective To explore the efficacy and safety of compound dichloride diisopropylamine (CDD) in the treatment of alcoholic fatty liver disease (AFLD) .Methods Ninety‐seven AFLD patients were randomly divided into research (n= 54) and control group (n= 43) .Research group was treated with intravenous CDD and control took orally insulin sensitizer metformin for 6 weeks .Effica‐cies were assessed according to the improvement condition of serum total cholesterol at the end of the 6th week and adverse reactions added up .Results At the end of the 6th week total effective rate was respec‐tively 9 8 .1% in research and 81 .4% in control group ,which showed significant difference ( P 〈 0 .01) . The incidence of adverse reactions was respectively 7 .4% in research and 14 .0% in control group ,which showed no significant difference (P 〉 0 .05) .Con‐clusion CDD has an evident effect and high safety in the treatment of AFLD and is worthy of clinical generalization and application .
作者 王翔燕
机构地区 济源市人民医院
出处 《临床心身疾病杂志》 CAS 2015年第5期136-137,共2页 Journal of Clinical Psychosomatic Diseases
关键词 酒精性脂肪性肝病 复方二氯二异丙胺 胰岛素增敏剂 二甲双胍 临床疗效 安全性 AFLD CDD insulin sensitizer metformin efficacy safety
  • 相关文献

参考文献6

二级参考文献21

  • 1Fan, Jian-Gao,Peng, Yong-De.Metabolic syndrome and non-alcoholic fatty liver disease:Asian definitions and Asian studies[J].Hepatobiliary & Pancreatic Diseases International,2007,6(6):572-578. 被引量:42
  • 2范建高.糖尿病与肝病的关系及其诊治对策[J].中华糖尿病杂志,2009,1(4). 被引量:30
  • 3Emin Altiparmak,Seyfettin K(o|¨)klü,Mesut Yalinkilic,Osman Yüksel,Bahattin Cicek,Ertugrul Kayacetin,Tülin Sahin.Viral and host causes of fatty liver in chronic hepatitis B[J].World Journal of Gastroenterology,2005,11(20):3056-3059. 被引量:53
  • 4Taylor BC, Yuan JM, Shamliyan TA, et al. Clinical outcomes in adults with chronic hepatitis B in association with patient and viral characteristics: A systematic review of evidence. Hepatology, 2009, 49(5 Suppl): S85-95.
  • 5Cheung O, Sanyal AJ. Hepatitis C infection and nonalcoholic fatty liver disease. Clin Liver Dis, 2008, 12: 573-585.
  • 6Fan JG, Chitturi S. Hepatitis B and fatty liver: causal or coincidental? J Gastroenterol Hepatol, 2008, 23: 679-681.
  • 7Cross TJ, Quaglia A, Hughes S, et al. The impact of hepatic steato- sis on the natural history of chronic hepatitis C infection. J Viral Hepat, 2009, 16: 492-499.
  • 8Fan JG, Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol, 2009, 50: 204-210.
  • 9Shi JP, Fan JG, Wu R, et al. Prevalence and risk factors of hepatic steatosis and its impact on liver injury in Chinese patients with chronic hepatitis B infection. J Gastroenterol Hepatol, 2008, 23: 1419-1425.
  • 10Petta S, Camma C, Di Marco V, et al. Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection. Am J Gastroenterol, 2008, 103: 1136-1144.

共引文献1190

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部